In lymphoma cell lines, Luxeptinib interferes with LYN-mediated activation of SYK, a necessary regulator of BTK, thus modulating BCR signaling [202], while it was also shown to downregulate proteins of the anti-apoptotic Bcl-2 family [203]. This evidence concerns the gene BCL2 and lymphoma.